Journal Article Ppublish 20 citations
PubMed: 34405573 DOI: 10.1002/cam4.4208
Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study.
Cancer Med 10(19):6705-6713
Authors: Tressie Herrmann, Angeline Ginzac, Ioana Molnar, Sébastien Bailly, Xavier Durando, Hakim Mahammedi
Affiliations
- Département d'Oncologie Médicale, Centre Jean PERRIN, Clermont-Ferrand, France.
- Université Clermont Auvergne, UFR Médecine, Clermont-Ferrand, France.
- INSERM U1240 Imgerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, Centre Jean PERRIN, Clermont-Ferrand, France.
- Centre d'Investigation Clinique, UMR 501, Clermont-Ferrand, France.
- Division de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, Clermont-Ferrand, France.
- Département d'Oncologie Médicale, CHU Gabriel Montpied, Clermont-Ferrand.
Abstract
BACKGROUND
Despite improvements in the management of renal cell carcinomas (RCC) with the advent of immunotherapy, only a few patients respond to these treatments. Predictors of response to nivolumab are currently being investigated but are still lacking.
AIM OF THE STUDY
To evaluate eosinophil levels and their variations during treatment as an accurate biomarker for outcome in metastatic RCC treated with nivolumab.
METHODS
A retrospective analysis was carried out for patients with metastatic RCC treated with nivolumab. Absolute eosinophil counts, their variation, and relative change were evaluated at six weeks. Relative eosinophil change was categorized in three groups (≥10%-decrease, no change, ≥10%-increase). Univariable and multivariable analyses were performed to determine whether eosinophils and their variations were prognostic markers for response at the first scan evaluation, progression-free survival, and overall survival.
RESULTS
Sixty-five patients aged on average 66 years, 68% men, and 77% with good or intermediate International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group were included. The median follow-up was 16.6 months. Median overall survival (OS) was not reached for good prognosis and was 22.5 and 6.5 months for intermediate and poor prognosis, respectively. An increase in eosinophils and relative eosinophil change at six weeks of nivolumab was associated with a good response to immunotherapy (p = 0.012 and p = 0.024 respectively). In the group of patients with a 10%-decrease in relative change, PFS reduced significantly compared to the other groups (p = 0.0044 with the 10%-increase group and p = 0.03 with the no-change group). This relative increase was independent of IMDC risks factors for better OS (HR = 3.3 [1.45-7.4]; p = 0.004). The eosinophil baseline level was not associated with response to treatment.
CONCLUSION
Eosinophil levels and relative eosinophil change at 6 weeks might be good prognostic markers for response to nivolumab for metastatic RCC, and were associated with better PFS and OS.
MeSH
Cells, Retrospective Studies, Neoplasms, Eosinophils, Carcinoma, Renal Cell, Immunotherapy, Nivolumab, Therapeutics, Prognosis
Cited by
- The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma. Cancers (Basel), 2022
- High Expression of a Cancer Stemness-Related Gene, Chromobox 8 (CBX8), in Normal Tissue Adjacent to the Tumor (NAT) Is Associated with Poor Prognosis of Colorectal Cancer Patients. Cells, 2022
- The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab. Clin Exp Med, 2024
- Prognostic Impact of Baseline Neutrophil-to-Eosinophil Ratio in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Therapy in Second or Later Lines. Cureus, 2022
- Peripheral eosinophils and immunotherapy response in patients with recurrent or metastatic HNSCC. Sci Rep, 2025
- Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial. BMJ Oncol, 2025
- Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Front Oncol, 2022
- Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma. Explor Target Antitumor Ther, 2024
- Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy. Nat Immunol, 2022
- Integrating Novel and Classical Prognostic Factors in Locally Advanced Cervical Cancer: A Machine Learning-Based Predictive Model (ESTHER Study). J Pers Med, 2025
- Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy. Cureus, 2022
- Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study. Cancer Med, 2022
- Predictive Value of Peripheral Blood Eosinophil Count on the Efficacy of Treatment with Camrelizumab in Combination with Lenvatinib in Patients with Advanced Hepatitis B-Associated Hepatocellular Carcinoma. Technol Cancer Res Treat, 2024